Single-Nucleus Transcriptomics Reveal Mechanisms of Cardiovascular Protection Against Ponatinib-Induced Cardiotoxicity Through ROCKs Deletion in Cardiomyocytes
By: Lei Wei, Yunjie Huang, Stephanie Shi and Jianjian Shi
References
- Aghel N, Gustafson D, Delgado D et al. (2023) High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. Leuk Lymphoma 64:2008–2017.
https://doi.org/10.1080/10428194.2023.2242990 - Aghel N, Lipton JH (2025) Cardiovascular disease in patients with chronic myeloid leukemia: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 7:668–682.
https://doi.org/10.1016/j.jaccao.2025.06.007 - Chang J, Xie M, Shah VR et al. (2006) Activation of rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA 103:14495–14500.
https://doi.org/10.1073/pnas.0601911103 - Chen EY, Tan CM, Kou Y et al. (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128.
https://doi.org/10.1186/1471-2105-14-128 - Cheng Z, Erhardt S, Wang J (2025) Rho/ROCK pathway as a therapeutic target in multiple diseases. Int J Drug Discov Pharm 4:100018.
https://doi.org/10.53941/ijddp.2025.100018 - Cortes J, Apperley J, Lomaia E et al. (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138:2042–2050.
https://doi.org/10.1182/blood.2021012082 - Gainor JF, Chabner BA (2015) Ponatinib: accelerated disapproval. Oncologist 20:847–848.
https://doi.org/10.1634/theoncologist.2015-0253 - Haguet H, Bouvy C, Delvigne AS et al. (2020) The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: An in-vitro study. Front Pharmacol 11:1007.
https://doi.org/10.3389/fphar.2020.01007 - Hamadi A, Grigg AP, Dobie G et al. (2019) Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response. Thromb Haemost 119:1112–1123.
https://doi.org/10.1055/s-0039-1688787 - Hnatiuk AP, Bruyneel AAN, Tailor D et al. (2022) Reengineering ponatinib to minimize cardiovascular toxicity. Cancer Res 82:2777–2791.
https://doi.org/10.1158/0008-5472.CAN-21-3652 - Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442–459.
https://doi.org/10.1002/ajh.25011 - Kuleshov MV, Jones MR, Rouillard AD et al. (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44(W1):W90–97.
https://doi.org/10.1093/nar/gkw377 - Latifi Y, Moccetti F, Wu M et al. (2019) Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood 133:1597–1606.
https://doi.org/10.1182/blood-2018-10-881557 - Li Q, Xu Y, Li X et al. (2012a) Inhibition of rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-beta1-TAK1. Toxicol Lett 211:91–97.
https://doi.org/10.1016/j.toxlet.2012.03.006 - Li Y, Zhu W, Tao J et al. (2012b) Fasudil protects the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: the differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. PLoS One 7:e48115.
https://doi.org/10.1371/journal.pone.0048115 - Madonna R, Moscato S, Polizzi E et al. (2021) Connexin 43 and connexin 26 involvement in the ponatinib-induced cardiomyopathy: Sex-related differences in a murine model. Int J Mol Sci 22:5815.
https://doi.org/10.3390/ijms22115815 - Madonna R, Pieragostino D, Cufaro MC et al. (2022) Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. J Cell Mol Med 26:1380–1391.
https://doi.org/10.1111/jcmm.17008 - Mali RS, Ramdas B, Ma P et al. (2011) Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell 20:357–369.
https://doi.org/10.1016/j.ccr.2011.07.016 - Matsumoto A, Manthey HD, Marsh SA et al. (2012) Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE(-/-) mice. Int J Cardiol 167:1282–1288.
https://doi.org/10.1016/j.ijcard.2012.03.172 - Miranda AMA, Janbandhu V, Maatz H et al. (2023) Single-cell transcriptomics for the assessment of cardiac disease. Nat Rev Cardiol 20:289–308.
https://doi.org/10.1038/s41569-022-00805-7 - Muzumdar MD, Tasic B, Miyamichi K et al. (2007) A global double-fluorescent Cre reporter mouse. Genesis 45:593–605.
https://doi.org/10.1002/dvg.20335 - O’Hare T, Shakespeare WC, Zhu X et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412.
https://doi.org/10.1016/j.ccr.2009.09.028 - Pouwer MG, Pieterman EJ, Verschuren L et al. (2018) The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med 5:55.
https://doi.org/10.3389/fcvm.2018.00055 - Sacha T, Krawczyk K (2025) Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: a review of management strategies. Hematol Transfus Cell Ther 47:103675.
https://doi.org/10.1016/j.htct.2024.04.124 - Samuels JD, Moore KA, Ennerfelt HE et al. (2023) The Alzheimer’s disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta-mediated pathology. Alzheimers Dement 19:4908–4921.
https://doi.org/10.1002/alz.13089 - Saussele S, Haverkamp W, Lang F et al. (2020) Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: Recommendations of a German expert consensus panel with focus on cardiovascular management. Acta Haematol 143:217–231.
https://doi.org/10.1159/000501927 - Shi J, Surma M, Wei L (2018) Disruption of ROCK1 gene restores autophagic flux and mitigates doxorubicin-induced cardiotoxicity. Oncotarget 9:12995–13008.
https://doi.org/10.18632/oncotarget.24457 - Shi J, Surma M, Yang Y et al. (2019) Disruption of both ROCK1 and ROCK2 genes in cardiomyocytes promotes autophagy and reduces cardiac fibrosis during aging. FASEB J 33:7348–7362.
https://doi.org/10.1096/fj.201802510R - Shi J, Surma M, Zhang L et al. (2013a) Dissecting the roles of ROCK isoforms in stress-induced cell detachment. Cell Cycle 12:1492–1500.
https://doi.org/10.4161/cc.24699 - Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: The effect of fasudil. J Cardiovasc Pharmacol 62:341–354.
https://doi.org/10.1097/FJC.0b013e3182a3718f - Shi J, Wei L (2024) ROCK1 deficiency preserves caveolar compartmentalization of signaling molecules and cell membrane integrity. FASEB Bioadv 6:85–102.
https://doi.org/10.1096/fba.2024-00015 - Shi J, Wu X, Surma M et al. (2013b) Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis 4:e483.
https://doi.org/10.1038/cddis.2013.10 - Shi J, Zhang L, Wei L (2011) Rho-kinase in development and heart failure: insights from genetic models. Pediatr Cardiol 32:297–304.
https://doi.org/10.1007/s00246-011-9920-0 - Shi J, Zhang YW, Summers LJ et al. (2008) Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy. J Mol Cell Cardiol 44:551–560.
https://doi.org/10.1016/j.yjmcc.2007.11.018 - Shi J, Zhang YW, Yang Y et al. (2010) ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice. J Mol Cell Cardiol 49:819–828.
https://doi.org/10.1016/j.yjmcc.2010.08.008 - Shibuya M, Suzuki Y, Sugita K et al. (1992) Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. results of a prospective placebo-controlled double-blind trial. J Neurosurg 76:571–577.
https://doi.org/10.3171/jns.1992.76.4.0571 - Shimokawa H, Sunamura S, Satoh K (2016) RhoA/Rho-kinase in the cardiovascular system. Circ Res 118:352–366.
https://doi.org/10.1161/CIRCRESAHA.115.306532 - Singh AP, Glennon MS, Umbarkar P et al. (2019) Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res 115:966–977.
https://doi.org/10.1093/cvr/cvz006 - Singh AP, Umbarkar P, Tousif S et al. (2020) Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib. Int J Cardiol 316:214–221.
https://doi.org/10.1016/j.ijcard.2020.05.077 - Skelly DA, Squiers GT, McLellan MA et al. (2018) Single-cell transcriptional profiling reveals cellular diversity and intercommunication in the mouse heart. Cell Rep 22:600–610.
https://doi.org/10.1016/j.celrep.2017.12.072 - Sohal DS, Nghiem M, Crackower MA et al. (2001) Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res 89:20–25.
https://doi.org/10.1161/hh1301.092687 - Stepanian A, Travers RJ, Tesfu A et al. (2025) Ponatinib, but not the new Abl-kinase inhibitor asciminib, activates platelets, leukocytes, and endothelial cell TNF signaling to induce atherosclerotic plaque inflammation, myocardial infarction, and stroke. Circulation 152:765–783.
https://doi.org/10.1161/CIRCULATIONAHA.125.073610 - Surma M, Handy C, Chang J et al. (2014) ROCK1 deficiency enhances protective effects of antioxidants against apoptosis and cell detachment. PLoS One 9:e90758.
https://doi.org/10.1371/journal.pone.0090758 - Tombor LS, John D, Glaser SF et al. (2021) Single cell sequencing reveals endothelial plasticity with transient mesenchymal activation after myocardial infarction. Nat Commun 12:681.
https://doi.org/10.1038/s41467-021-20905-1 - Tousif S, Singh AP, Umbarkar P et al. (2023) Ponatinib drives cardiotoxicity by S100A8/A9-NLRP3-IL-1beta mediated inflammation. Circ Res 132:267–289.
https://doi.org/10.1161/CIRCRESAHA.122.321504 - Wang F, He Q, Gao Z et al. (2021) Atg5 knockdown induces age-dependent cardiomyopathy which can be rescued by repeated remote ischemic conditioning. Basic Res Cardiol 116:47.
https://doi.org/10.1007/s00395-021-00888-2 - Wang N, Guan P, Zhang JP et al. (2011) Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway. Food Chem Toxicol 49:2975–2982.
https://doi.org/10.1016/j.fct.2011.06.080 - Wei L, Surma M, Shi S et al. (2016) Novel insights into the roles of Rho kinase in cancer. Arch Immunol Ther Exp 64:259–278.
https://doi.org/10.1007/s00005-015-0382-6 - Wolff AW, Bidner H, Remane Y et al. (2024a) Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD). Front Aging Neurosci 16:1308577.
https://doi.org/10.3389/fnagi.2024.1308577 - Wolff AW, Peine J, Hofler J et al. (2024b) SAFE-ROCK: a Phase I trial of an oral application of the ROCK inhibitor Fasudil to assess bioavailability, safety, and tolerability in healthy participants. CNS Drugs 38:291–302.
https://doi.org/10.1007/s40263-024-01070-7 - Wu DJ, Xu JZ, Wu YJ et al. (2009) Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein e-knockout mice. Atherosclerosis 207:68–73.
https://doi.org/10.1016/j.atherosclerosis.2009.04.025 - Xie Z, Bailey A, Kuleshov MV et al. (2021) Gene set knowledge discovery with enrichr. Curr Protoc 1:e90.
https://doi.org/10.1002/cpz1.90 - Yu B, Osman AEG, Sladojevic N et al. (2022) Involvement of rho-associated coiled-coil containing kinase (ROCK) in BCR-ABL1 tyrosine kinase inhibitor cardiovascular toxicity. JACC CardioOncol 4:371–383.
https://doi.org/10.1016/j.jaccao.2022.06.004 - Yusuf AM, Qaisar R, Al-Tamimi AO et al. (2022) Cardiomyocyte-GSK-3beta deficiency induces cardiac progenitor cell proliferation in the ischemic heart through paracrine mechanisms. J Cell Physiol 237:1804–1817.
https://doi.org/10.1002/jcp.30644 - Zhang J, Bian HJ, Li XX et al. (2010) ERK-MAPK signaling opposes rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning. Mol Med 16:307–315.
https://doi.org/10.2119/molmed.2009.00121 - Zhang YM, Bo J, Taffet GE et al. (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 20:916–925.
https://doi.org/10.1096/fj.05-5129com - Zhong L, Li Y, Xiong L et al. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6:201.
https://doi.org/10.1038/s41392-021-00572-w
DOI: https://doi.org/10.2478/aite-2026-0027 | Journal eISSN: 1661-4917
Language: English
Submitted on: Jun 28, 2026
Accepted on: Sep 2, 2026
Published on: Oct 30, 2026
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2026 Lei Wei, Yunjie Huang, Stephanie Shi, Jianjian Shi, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution 4.0 License.